Alumis Inc. surged on Phase 3 psoriasis data for envudeucitinib. Click for this look at ALMS stock and why I am bullish on ...
The psoriasis market is experiencing steady growth, driven by rising disease prevalence, improved diagnosis rates, and ...
In both trials, envudeucitinib showed greater skin clearance than placebo on both co-primary endpoints at week 16.
Zacks Investment Research on MSN
ALMS Surges as Envudeucitinib Meets Goals in Plaque Psoriasis Studies
Shares of Alumis ALMS surged 95.3% on Jan. 6, after the company announced positive top-line data from its two phase III ...
Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Limited ("Sun Pharma"), is pleased to ...
Both drugs also showed in their phase 3 trials that they were superior to Amgen's oral PDE4 inhibitor Otezla (apremilast), ...
NB-UVB phototherapy may restore adalimumab efficacy in chronic plaque psoriasis after treatment failure. Learn more about ...
Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque ...
Shares of Alumis gained on plans to share topline data from a Phase 3 trial evaluating envudeucitinib to treat moderate-to-severe plaque psoriasis. The stock rose 8.9% to $9.05 in after-hours trading ...
New treatments for psoriasis are available, and more advanced options may be approved for use soon. These include steroid-free topicals, targeted biologics and oral medications, and smartphone-powered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback